Targeting Cancer Cells with Greater Accuracy
Clinical trial results suggest NeoPulse may enhance local activity of the anti-cancer drug bleomycin while minimizing systemic side effects.
NeoPulse uses the OMS system to destroy cancer cells using less harmful doses of bleomycin, a highly effective but also highly toxic anti-cancer drug.
Traditionally, bleomycin must be administered by intravenous infusion. Because this method targets cancer cells inefficiently, high doses must be used and significant side effects are common.
Using NeoPulse to electroporate and directly target cancerous cells with bleomycin, an effective result can be achieved with 1/20th of a traditional chemotherapy dose.
Intensifying an already powerful drug
Bleomycin is proven to destroy cancer cells by attacking their DNA via an apoptotic or “suicidal” mechanism. Electroporation can potentially increase the uptake of the drug. Studies in mice have demonstrated that the effectiveness of bleomycin is increased when used in combination with electroporation versus injecting bleomycin by itself.
Even more advantageous, the pores of treated cells close shortly after introduction of the drug, trapping it within. Tests show that electroporated cells retain more of the drug, and retain it for a longer period, thereby increasing the effectiveness of the treatment.
Benefits of NEOPULSE:
Reduced side effects. A fraction of the conventional systemic dose is delivered using the OMS technology, which may reduce or eliminate the systemic side effects associated with bleomycin.
Quality of life. NeoPulse delivers a highly targeted and minimally invasive therapy. The treatment is less likely to involve the removal of healthy tissue therefore reducing the impact on quality of life.
Lower treatment costs. A pharmacoeconomic data analysis suggests that NeoPulse therapy costs significantly less and that it’s also less likely to require costly post-treatment care than surgical alternatives.
Greater treatment accessibility. Patients unable to withstand surgery or conventional chemotherapy may still be able to qualify for less invasive, electroporation-based treatment.
Pre-clinical and clinical data from Phase 1 through 4 clinical trials demonstrate NeoPulse technology holds promise as a treatment for solid tumors, such as melanoma, basal cell carcinoma, squamous cell carcinoma, and liver and pancreatic cancers, with observable cancer cell destruction.
Success in killing locally recurrent or secondary primary tumor.
On average, patients who received our treatment lived 8 months (equal to surgery).
Success in killing local primary tumors without any recurrence (monitored for 8 months)